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A B S T R A C T
Patients with functional or anatomic asplenia are at a
significantly increased risk of overwhelming infection,
particularly involving the encapsulated bacteria
Streptococcus pneumoniae and Haemophilus influenzae.
The risk is highest in infants and young children, but
adults also have an increased risk of infection.
Preventive strategies are very important and fall into
three major categories: immunoprophylaxis, antibiotic
prophylaxis and education. Studies have shown that many
asplenic patients are unaware of their increased risk for
serious infection and the appropriate health precautions
that should be undertaken. In this article we emphasise the
need for preventive measures in hyposplenic and asplenic
patients. We discuss the value of newly developed conjugate
vaccines and the need for revaccination. Finally we draw
up a recommendation for the preventive management in
functional and anatomical asplenic patients.
I N T R O D U C T I O N
Patients with functional or anatomic asplenia are at a
significantly increased risk of overwhelming infection
(postsplenectomy sepsis [PSS]), particularly involving the
encapsulated bacteria Streptococcus pneumoniae and
Haemophilus influenzae.1-3 In 1919, Morris and Bullock
recognised the importance of the spleen in resistance to
infection in studying splenectomised rats.4 The first
reported case of postsplenectomy infection was by
O’Donnel in 1929.5 It was not until 1952 that attention
focussed on the subject, when King and Shumacker
reported five cases of severe infection in infants who had
undergone splenectomy for spherocytosis.6
Preventive strategies against PSS fall into three major
categories: immunoprophylaxis, antibiotic prophylaxis,
and education. Different studies report a low adherence
to these preventive measures in hyposplenic and asplenic
patients.1,7-10 Family practitioners and medical specialists
should inform the patients at risk and make every effort
to increase the coverage of recommended vaccines and
chemoprophylaxis in this group. 
Furthermore, the recent development of new conjugate
vaccines has enhanced the options for preventive manage-
ment in (functional) asplenic patients. This article calls
attention to the importance of vaccination after splenectomy
and reviews the recent developments with relation to
immunisation, revaccination and other preventive measures. 
S P L E N E C T O M Y  A N D  H Y P O S P L E N I S M
Surgical removal of the spleen is performed for several
reasons, including trauma, immunological diseases,
hypersplenism and malignancy.2 In a major university
hospital the most common reasons for performing
splenectomy were haematological and immunological
diseases (31%), while trauma accounted for only 16%
(table 1). Figure 1 shows the absolute incidence of
splenectomy in the Netherlands from 1997 to 2002.
Growing awareness of possible long-term complications
has more recently led to an increasingly conservative
approach toward resection and greater efforts to preserve
splenic tissue.1,2,11 In Hodgkin’s disease, splenectomy is
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no longer a routine procedure.12 However, the procedure
remains important in the management of patients
with hereditary haemolytic anaemias, spherocytosis in
particular.2
Functional hyposplenism is associated with a wide variety
of diseases, including several immunological and haem-
atological diseases. In infants, asplenia is usually linked
to serious organ malformations (Ivemark’s syndrome),
but isolated congenital asplenia diagnosed in adults can
occur.2 The true incidence of hyposplenism is unknown,
mainly because the recognition requires a high index of
suspicion. 
The presence of Howell-Jolly bodies in the erythrocytes
on a peripheral blood film is an important clue to the
diagnosis of asplenia or functional hyposplenism.
Howell-Jolly bodies are nuclear remnants normally
removed by the spleen and may not occur with mild
hyposplenism. Their presence in erythrocytes is thought
to represent a risk for PSS.1,7,13 The ‘pocked erythrocyte
count’ (pit count) is a more sensitive indicator of splenic
clearance and can be visualised by interference phase
microscopy. Pocks are membrane vesicles removed only
by the spleen, and the presence of more than 12% pocked
red cells is indicative of asplenia.1,14-16 A pocked erythrocyte
count of less than 2% is expected in normal persons and
a percentage of more than 3.5% is strongly correlated
with functional hyposplenia.15,16
P O S T S P L E N E C T O M Y  S E P S I S
Incidence
Singer17 defined postsplenectomy sepsis (PSS) as septicaemia,
meningitis, or pneumonia that is usually fulminant and
occurs days to years after removal of the spleen.
Estimates of the incidence of postsplenectomy sepsis
have frequency been fairly variable for many reasons,
including different disease definitions, duration of follow-
up, and stratification for age, splenectomy cause and
underlying disease.1,2
The risk of PSS is highest in children, especially those
under two years of age and during the first years after
splenectomy.1,3,17,18 There are, however, reported cases of
fulminant sepsis 20 to 40 years after splenectomy, indicating
that postsplenectomy patients carry a lifelong risk.17,19-21
The incidence of infection after splenectomy is usually
quoted from the major collective review of Singer published
in 1973, who evaluated 2795 patients with asplenia.17 The
incidence of PSS was 4.25% with a mortality rate of 2.52%.
Singer concluded that death from postsplenectomy sepsis
is 200 times as prevalent as death due to sepsis in the
population at large. However, not all studies confirmed this
considerably higher risk for sepsis after splenectomy.3,22
Holdsworth et al. reported a collective review of the 
literature on PSS from 1952 to 1987.3 In this study the
incidence of infection after splenectomy in children
under 16 years old was 4.4% with a mortality rate of
2.2%. The corresponding figures for adults were 0.9%
and 0.8%. Walker prospectively observed 16 (2%) severe
infections in 821 children undergoing splenectomy with
a 70% five-year follow-up.23
The risk of PSS can also be stratified by underlying disease.
The lowest risk is related to trauma, intermediate risk to
spherocytosis, idiopathic thrombocytic purpura, or portal
hypertension, and highest risk in thalassaemia or
Hodgkin’s disease.2,17
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Table 1
Indication for splenectomy in the Erasmus University Medical
Centre from 1998 to 2002 (Rotterdam, the Netherlands)*
INDICATION OF SPLENECTOMY NUMBER (%)
Haematological and immunological diseases 73 (31%)
Abdominal malignancies 54 (23%)
Trauma 38 (16%)
Miscellaneous 57 (24%)
Unknown 13 (6%)
Total 235 (100%)
* Figures derived from the department of Medical Data Processing, Erasmus
University Medical Centre.
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Figure 1
Incidence of splenectomy in the Netherlands (total
number)*
* Figures derived from Prismant, Utrecht, the Netherlands.
Typical presentation and prognosis
PSS may have a short prodrome of low-grade fever with
chills, pharyngitis, muscle aches, vomiting, or diarrhoea.
In a few hours this stage can rapidly evolve into severe
septic shock with true rigors, hypotension and anuria.
There is usually no clinical evidence of a local tissue
infection. In children younger than five years of age, focal
infections, particularly meningitis, are more common.3
In severe cases rapid deterioration is often accompanied
by disseminated intravascular coagulopathy (DIC) with
adrenal haemorrhage (Waterhouse-Friderichsen syndrome).
Other complications include purpura fulminans, extremity
gangrene, convulsions and coma.1,2,7
The mortality rates of PSS range from 50 to 70%, despite
appropriate antimicrobial therapy and intensive medical
treatment.3,24 Holdsworth et al. reported an overall fatality
rate of 55.3% in 349 episodes.3 The dramatic nature of the
illness is further reflected by the time from initial symptoms
to death, with 68% of the deaths occurring within 24
hours and 80% within 48 hours.2,3 These data emphasise
the importance of prevention of PSS. 
Microbiology of postsplenectomy sepsis
Streptococcus pneumoniae is the most common organism
involved in PSS and the causative agent in 50 to 90% of the
cases.1-3,17,24 A predominant polysaccharide serotype is not
found, and there is no difference in serotype distribution
involved in PSS from that in other forms of pneumococcal
infection.2
Haemophilus influenzae type b is the second most common
organism related to PSS.1-3,24 Most cases occur in children
younger than 15 years of age, 86% in one review.3 Overall
incidence of invasive disease decreased significantly with
wide usage of conjugated H. influenzae type b vaccine and
probably results in a decrease in the overall number of
PSS cases associated with H. influenzae, with more of the
remaining infection occurring in older, nonvaccinated
persons.2 Low virulent non-b capsular strains (a, c, d, e
and f) may cause invasive infection, but are not relevant
in PSS.1
Neisseria meningitidis has been cited as the third most
common cause of PSS.1-3 However, there is no evidence to
suggest that meningococcaemia occurs more frequently
or is more severe in asplenic or hyposplenic patients
compared with healthy persons.1,2
Capnocytophaga canimorsus is a Gram-negative rod and
part of the normal flora of dogs and cats. This bacillus
can cause fulminant sepsis (purpura fulminans) following
dog or cat bites and scratches.1,2,25 Previous splenectomy,
alcoholism, and glucocorticosteroid therapy are the
most important risk factors for C. canimorsus sepsis.
Approximately 35% of the cases of C. canimorsus
septicaemia are associated with asplenia.25,26
Salmonella species have also been associated with PSS.
Salmonella is a prominent pathogen in children with sickle
cell anaemia and splenic dysfunction.1,2,24,27,28
Less common bacteria isolated from splenectomised
patients include Escherichia coli, Staphylococcus aureus,
Pseudomonas aeruginosa, Enterococcus species, Bacteroides
species, Plesiomonas shigelloides, Eubacterium plautii and
Pseudomonas pseudomallei.1,2,19
Asplenic and hyposplenic patients appear to be more
susceptible to serious infections with protozoans following
tick bites (Babesia microti in North America and Babesia bovis
in Europe).1,2,7,29,30 These micro-organisms infect erythrocytes
that are sequestered in the spleen. There is no consistent
evidence that malaria follows a significantly more severe
course in splenectomised patients.1,2,29,31
P R E V E N T I O N  O F  I N F E C T I O N S  I N
H Y P O S P L E N I C  A N D  A S P L E N I C
P A T I E N T S
Immunoprophylaxis
Pneumococcal-polysaccharide vaccine 
Pneumococcal immunisation with polyvalent capsular
polysaccharide vaccine is uniformly recommended for
asplenic and hyposplenic patients.1,2,7,18,19,32,33 The currently
available pneumococcal polysaccharide vaccine (PPV23)
contains capsular polysaccharides from 23 serotypes,
responsible for at least 85 to 90% of the serotypes that
cause invasive pneumococcal infections among children
and adults.34 Bacterial capsular polysaccharides induce
antibodies primarily by T-cell independent mechanisms.
Therefore, antibody response to most pneumococcal
capsular types is generally poor in children less than two
years of age, whose immune systems are immature.1,18,34,35
The antibody response is also decreased in children
under the age of five years.
Healthy asplenic adults have been found to have normal
or nearly normal antibody responses to polysaccharide
antigens by most36-40 but not all41 investigators. Siber et al.
compared the antibody response to pneumococcal capsular
polysaccharide vaccine in patients with Hodgkin’s disease,
patients with asplenia due to other causes and in healthy
adults. The antibody responses to immunisation were
similar in these three groups. However, patients with
Hodgkin’s disease who started chemotherapy less than
ten days after immunisation showed a significantly lower
antibody response.37 Impaired antibody response is related
to underlying disease and the medical treatment of this
disease. In Hodgkin’s disease, antibody response improves
as the time of immunisation after chemotherapy or radiation
increases.42
Giebink et al. reported a normal antibody response in
splenectomised children (mean age, 11.6 years) to pneumo-
coccal polysaccharide vaccine.36 Lee et al. concluded PPV23
Melles, et al. Infections in asplenic patients.
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to be safe and immunogenic in splenectomised children
as well as healthy children above two years of age.43
Several studies conclude polysaccharide pneumococcal
vaccination to be efficacious in preventing PSS in hypo-
splenic and asplenic patients.32,36,37,44-46 Konradsen et al.
reported a considerable decrease of PSS in children since
1982, when antibiotic prophylaxis and pneumococcal
vaccination were first recommended in splenectomised
patients.32
The vaccine should be given a minimum of two weeks
before elective splenectomy to ensure an optimal anti-
body response. After emergency splenectomy, patients
should be immunised soon after surgical recovery or at
time of discharge from the hospital.1,2,7,18,33 Immunisation,
however, should be delayed at least six months after
immunosuppressive chemotherapy or radiotherapy.18 To
tide over this period, prophylactic antibiotics should be
given. Hyposplenic patients should be immunised as
soon as the diagnosis is made. Asplenic or hyposplenic
children should be immunised with PPV23 after their
second birthday (table 2).35
There is no consensus on the reimmunisation policy in
hyposplenic and asplenic patients. Several studies advise
revaccination with PPV23, because specific antibody levels
decrease in high-risk patients as well as in healthy patients
for a few years after first vaccination.36,47-51 Weintrub et al.
studied the duration of antibody response of pneumococcal
polysaccharide vaccine and the effect of booster immunisa-
tion in patients with sickle cell anaemia.50 They concluded
that antibody levels had fallen by three to five years after
first immunisation. Mean antibody levels after booster
immunisation were significantly increased (which is not
what one would expect from a thymus-independent vaccine),
and no serious adverse events were noted. Giebink et al.
reported in splenectomised patients a linear serum anti-
body concentration decline by 24 to 32% from the peak
antibody level during the first year after vaccination.36
These data suggest a need for revaccination after three to
four years. Rutherford et al. advised revaccination
between two and six years after splenectomy.47
Jackson et al. studied the safety of revaccination with the
pneumococcal polysaccharide vaccine.51 They demonstrated
that self-limiting local injection site reactions occur more
frequently following revaccination (11%) compared with
first vaccination (3%). The risk of these local reactions
was significantly correlated with prevaccination geometric
mean antibody concentration. However, the risk of adverse
events does not represent an absolute contradiction to
revaccination with PPV23 for high-risk groups.51
The USA Centres for Disease Control (CDC) and
Prevention Advisory Committee on Immunisation
Practices (ACIP) recommend revaccination once with
PPV23 in hyposplenic and asplenic patients after five
years.34 Revaccination after three years may be considered
for children with functional or anatomic asplenia, who
would be aged ≤10 years at the time of revaccination.
Because data are insufficient concerning the safety of
pneumococcal polysaccharide vaccine when administered
three or more times, revaccination following a second
dose is not routinely recommended.34
Pneumococcal conjugate vaccine
Recently, a protein-polysaccharide conjugate vaccine (PCV7)
was licensed in the United States for use in infants and
young children. In 2001, this vaccine was registered in the
Netherlands. Conjugation of polysaccharides to proteins
changes the nature of the antipolysaccharide response
from T-lymphocyte independent to T-dependent. This
antigen complex stimulates a T-helper cell response,
leading to immunogenicity in early infants (>2 months of
age), stimulation of high levels of IgG isotype antibodies
and enhanced immunological memory responses.35,52,53
The vaccine contains capsular polysaccharides from
seven serotypes, each coupled with a nontoxic variant of
diphtheria toxin.52 These seven serotypes are responsible
for approximately 64% of the invasive pneumococcal
infections in children under the age of two years in the
Netherlands.35 PCV7 is safe and effective for use in the
general population.54,55 A large-scale efficacy trial in
California (Kaiser Permanente Vaccine Study) concluded
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Table 2
Recommended schedule for PCV7 and PPV23 vaccination among infants and children with (functional) asplenia35,52*
AGE AT FIRST DOSE SCHEDULE FOR PCV7 SCHEDULE FOR ADDITIONAL VACCINATION WITH PPV23 (AGE)
2-6 months 3 doses (4-8 weeks apart) 24 months
1 dose at age 12-15 months
7-11 months 2 doses (6-8 weeks apart) 24 months
1 dose at age 12-15 months
12-23 months 2 doses (8 weeks apart) 24 months (≥2 months after last dose of PCV7)
24-59 months 2 doses (6-8 weeks apart) ≥2 months after last dose of PCV7
* Recommendations for adults with (functional) asplenia, see text.
an efficacy of 97.4% in preventing invasive pneumococcal
disease caused by vaccine serotypes in children with PCV7.54
The CDC and ACIP (USA) recommend that the vaccine
should be used in all children aged 2 to 23 months and in
children aged 24 to 59 months who are at increased risk
for pneumococcal disease, such as children with functional
or anatomic asplenia.52
The Health Council of the Netherlands recommends
introducing vaccination against pneumococci with PCV7 in
the National Vaccination Programme as soon as combined
administration of DKTP and Hib vaccines is possible. A
combined vaccine for meningococcal C and pneumococcal
infections will probably be available in early 2005. If
research shows this combined vaccine to be safe, effective
and efficient it would make sense to start using it on
young infants.56
In expectation of the introduction of PCV7 in the National
Vaccination Programme of the Netherlands, the vaccine
should be administered to children less than five years of
age who are at increased risk for pneumococcal
infection.35 Children with functional or anatomic asplenia
who have completed the PCV7 vaccination series before
the age of two years should receive one additional dose of
PPV23 at two years of age (>2 months after the last dose
of PCV7) to provide additional serotype coverage.34,35,52 So,
children with functional or anatomical asplenia between
two and five years should be vaccinated with both vaccines
(table 2). Of some concern are the results of a Dutch
collaborative study showing that the combined vaccine
strategy did not prevent infections in children with
recurrent otitis media. A shift towards nasopharyngeal
carriage of nonvaccine pneumococcal serotypes could be
the explanation.57 The need for reimmunisation is
unclear.52 Current data do not support a recommendation
to replace PPV23 with PCV7 among older children (>5 years)
and adults.52 The proportion of invasive pneumococcal
isolates covered by PCV7 is only 50 to 60% among older
children and adults, in contrast with 80 to 90% coverage
by PPV23 among this older group. Additional studies are
needed to evaluate potential use of PCV7 in combination
with PPV23 among adults at increased risk for pneumo-
coccal infection.
Haemophilus influenzae type b immunisation
Although the efficacy and utility of vaccination against H.
influenzae type b (Hib) in preventing PSS is less clear
than pneumococcal vaccination, the Hib vaccine is being
recommended for hyposplenic and asplenic individuals in
the recent literature.1,2,7,18,19,33
In 1993, the Hib vaccine was introduced in the National
Vaccination Programme in the Netherlands. Thus, most
children up to 10 years of age have already been vaccin-
ated. Many adults have acquired immunity against 
Hib through natural exposure, but this may not provide
adequate protection in hyposplenic or asplenic
patients.1,2,18 The H. influenzae conjugate vaccine
should be administered to all adults and children at
risk who have not been vaccinated so far.1,2,18,33,58 The
vaccine has been shown to be immunogenic in patients
with impaired splenic function.58-61 The need for 
reimmunisation is unclear.1,2,7,18,60
Meningococcal immunisation
There are two meningococcal vaccines based on capsular
polysaccharides: the bivalent meningococcal vaccine
(serogroups A and C) and the quadrivalent meningococcal
vaccine (serogroups A, C, W135 and Y). Ruben et al.
concluded that bivalent meningococcal vaccine is
immunogenic in asplenic persons, with the exception of
those with lymphoma who had received prior chemotherapy
and radiotherapy.62 Because of the short duration of
protection (two to three years) and the absence of protection
against the most common serogroup B, these vaccines
are not recommended routinely for asplenic patients.1,2,7,18
However, it should be given to asplenic patients travelling
to areas with increased risk of group A infection, such as
sub-Saharan regions.1,2,18
The recently available meningococcal conjugate vaccine is
composed of a serogroup C meningococcal polysaccharide
conjugated to tetanus toxoid. In 2002 this vaccine was
introduced in the National Vaccination Programme of the
Netherlands. In contrast to the bivalent and quadrivalent
meningococcal vaccines, this conjugated vaccine provides
long-lasting immunity and is also effective in children
under the age of two years. With the increasing number
of infections by Neisseria meningitidis group C in Europe
and the advantages of conjugated vaccines, patients with
asplenia should receive this vaccine.33 Travel to areas
where other serogroups of meningococci are prevalent is
an indication for revaccination with the bivalent or
quadrivalent vaccine.1,2,18,33 A meningococcal vaccine that
covers serogroup B strains is still not available. 
Influenza immunisation
Yearly administration of influenza vaccination is 
recommended, because it reduces the risk of 
secondary pneumococcal and Haemophilus influenzae
infections.1,2,7,18,19,33
Vaccine failure
Sporadic cases of pneumococcal and other vaccine failures
have been reported in immunised postsplenectomy
patients.63-68 So vaccination by itself should never allow a
false sense of security. Furthermore, there are several
other causative agents related to PSS which can not be
vaccinated for.
Melles, et al. Infections in asplenic patients.
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Prophylactic or empiric use of antibiotics
Most authorities recommend antibiotic prophylaxis for
asplenic or hyposplenic children, especially for the first
two years after splenectomy.19,20,32,69 Some investigators
advocate continuing chemoprophylaxis until the age of 16
to 18 in children and for at least five years in adults.18,20
Traditionally, a daily dose of oral penicillin or amoxicillin
is the regime of choice.1,2,18,20 Local resistance patterns
or penicillin allergy may dictate the need to use other
antibiotics.18,33 Gaston et al. reported an 84% reduction in
pneumococcal bacteraemia with the use of oral penicillin
prophylaxis in children with sickle cell anaemia.69
Whether (long-term) antibiotic prophylaxis in children is
still necessary after the introduction of the pneumococcal
conjugate vaccine has to be investigated. 
The value of prophylactic antibiotics in older children
or in adults has never been evaluated adequately in a
clinical trial.70,71 Long-term prophylaxis may be a risk
factor for the selection of resistant strains, and efficacy
may be reduced by noncompliance.2,19,70,71 Therefore,
long-term antibiotic prophylaxis in adults is not generally
recommended.24,70,71
Access to ‘stand-by’ antibiotics is advised for asplenic
patients in the current literature.18,19,29,33,72 ‘Stand-by’
antibiotics should be taken at the first sign of infection
(increase in body temperature, malaise or shivering) if
the patient is unable to obtain prompt medical attention.
However, in such situations medical help should still be
sought without delay. A disadvantage of this strategy is
the ‘overtreatment’ of many viral illnesses,19 but to our
opinion the benefits outweigh here. 
Patient education
Patient education is an important and effective strategy in
preventing PSS.1,2,7,18,19 Studies have shown that up to
84% of postsplenectomy patients are unaware of their
increased risk for serious infection and the appropriate
health precautions that should be undertaken.7-10 Patients
should be informed about their increased susceptibility to
certain infections, the potential seriousness of PSS and
its possible very rapidly progressive and life-threatening
course. They should be instructed to notify their physician
of any acute febrile illness, especially if associated with rigors
or systemic symptoms.1,2,7,18,19,29 The different preventive
strategies, as immunisation and the importance of re-
vaccination, antibiotic prophylaxis and the need to carry
‘stand-by’ antibiotics, have to be discussed with the
patients. Several investigators encourage patients to
wear a medical alert bracelet or necklace and to carry a
card documenting immunisation, any prophylactic
antibiotics in use, and a plan for emergencies.1,2,18,19,29,33
Patients should inform any new healthcare professionals,
including dentists, of their asplenic or hyposplenic 
status.
Patients should be educated about the increased risk for
travel-related infections, such as babesiosis. The importance
of malarial prophylaxis and (simple) measures to reduce
exposure to malaria parasites should be emphasised.18,20
Asplenic patients travelling to sub-Saharan Africa, India
and Nepal should receive the bivalent menigococcal
(serogroups A and C) vaccine.18 Patients should keep a
therapeutic course of antibiotics with them during periods
of travel, taking into account the regional resistance patterns
of common pathogens.1,18,20 Patients should be warned to
seek prompt treatment of even a minor dog bite or other
animal bite in view of the increased susceptibility to
infection by C. canimorsus.7,10,18,19,33
C O N C L U S I O N  A N D  
R E C O M M E N D A T I O N S
Fulminant infection, such as postsplenectomy sepsis, is a
major long-term risk in functional and anatomical
asplenic patients. In consideration of the (recent) literature
and the development of new vaccines we recommend a
series of preventive measures for hyposplenic and
asplenic patients. These are represented in table 3. 
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Table 3
Recommendation for preventive measures in functional
and anatomical asplenic patients
IMMUNISATION AGE
Pneumococcal polysaccharide vaccine (PPV23)* >2 years (table 2)
Pneumococcal conjugate vaccine (PCV7) >2 months 
(table 2)
<5 years 
Haemophilus influenzae type b vaccine >2 months 
Meningococcal serogroup C conjugate vaccine >2 months 
Influenzae vaccine** >6 months
ANTIBIOTIC PROPHYLAXIS***
Daily antibiotic prophylaxis for the first two years <18 years
after splenectomy in children 
‘Stand-by’ antibiotics All
PATIENT EDUCATION All
* Revaccination: after five years (after three years for children <10 years of
age at time of revaccination), ** revaccination: yearly, *** amoxicillin or
claritromycin.
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